Search research articles
Contact Us
Filters
Showing results (141-150 of 178) with videos related to
Page
of 18
Sort By:
Gut
|
June 22, 2002
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
B R Yacyshyn, W Y Chey, J Goff, et al.
Cancer Immunology, Immunotherapy : CII
|
January 1, 1993
Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene
L Ding, E N Lalani, M Reddish, et al.
The Journal of Rheumatology
|
March 3, 2016
How to Attract Trainees, a Pan-Canadian Perspective: Phase 1 of the "Training the Rheumatologists of Tomorrow" Project
Alfred Cividino, Volodko Bakowsky, Susan Barr, et al.
EJNMMI Reports
|
February 28, 2025
Comparison of [<sup>18</sup>F]fluorodeoxyglucose and [<sup>68</sup>Ga]Gallium DOTA-TATE in patients with active giant cell arteritis
Alison H Clifford, Jonathan Abele, Ryan Hung, et al.
Arthritis Care & Research
|
April 27, 2026
Perceived Impacts and Predictors of Cannabis Products used by Rheumatology Patients in Alberta: A Multivariable Analysis of Cross-sectional Survey Data
Susan Zhang, Samuel A J Lowe, Frank Sun, et al.
The EMBO Journal
|
April 15, 1999
Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase C-gamma1 and Ras activation
B L Williams, B J Irvin, S L Sutor, et al.
Gastroenterology
|
September 22, 2009
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis
William J Sandborn, Jaroslaw Regula, Brian G Feagan, et al.
Journal of the American Academy of Dermatology
|
October 13, 2022
Skin disorders and interstitial lung disease: Part II-The spectrum of cutaneous diseases with lung disease association
Lydia Ouchene, Anastasiya Muntyanu, Deborah Assayag, et al.
The Journal of Physiology
|
March 30, 2024
Intrinsic motoneuron properties in typical human development
Ghazaleh Mohammadalinejad, Babak Afsharipour, Alex Yacyshyn, et al.
Gastroenterology
|
November 13, 2019
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
William J Sandborn, Laurent Peyrin-Biroulet, Jinkun Zhang, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 178) with videos related to
Sort By:
Page
of 18
Gut
|
June 22, 2002
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
B R Yacyshyn, W Y Chey, J Goff, et al.
Cancer Immunology, Immunotherapy : CII
|
January 1, 1993
Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene
L Ding, E N Lalani, M Reddish, et al.
The Journal of Rheumatology
|
March 3, 2016
How to Attract Trainees, a Pan-Canadian Perspective: Phase 1 of the "Training the Rheumatologists of Tomorrow" Project
Alfred Cividino, Volodko Bakowsky, Susan Barr, et al.
EJNMMI Reports
|
February 28, 2025
Comparison of [<sup>18</sup>F]fluorodeoxyglucose and [<sup>68</sup>Ga]Gallium DOTA-TATE in patients with active giant cell arteritis
Alison H Clifford, Jonathan Abele, Ryan Hung, et al.
Arthritis Care & Research
|
April 27, 2026
Perceived Impacts and Predictors of Cannabis Products used by Rheumatology Patients in Alberta: A Multivariable Analysis of Cross-sectional Survey Data
Susan Zhang, Samuel A J Lowe, Frank Sun, et al.
The EMBO Journal
|
April 15, 1999
Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase C-gamma1 and Ras activation
B L Williams, B J Irvin, S L Sutor, et al.
Gastroenterology
|
September 22, 2009
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis
William J Sandborn, Jaroslaw Regula, Brian G Feagan, et al.
Journal of the American Academy of Dermatology
|
October 13, 2022
Skin disorders and interstitial lung disease: Part II-The spectrum of cutaneous diseases with lung disease association
Lydia Ouchene, Anastasiya Muntyanu, Deborah Assayag, et al.
The Journal of Physiology
|
March 30, 2024
Intrinsic motoneuron properties in typical human development
Ghazaleh Mohammadalinejad, Babak Afsharipour, Alex Yacyshyn, et al.
Gastroenterology
|
November 13, 2019
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
William J Sandborn, Laurent Peyrin-Biroulet, Jinkun Zhang, et al.
Page
of 18